RecruitingPhase 1Phase 2NCT07070518

Study of GV20-0251 in Participants With Solid Tumor Malignancies

An Open-Label Phase 1/2A Study of GV20-0251 in Participants With Advanced and/or Refractory Solid Tumor Malignancies

Sponsor

GV20 Therapeutics

Enrollment

350 participants

Start Date

Jul 11, 2025

Study Type

INTERVENTIONAL

Conditions

Solid Tumor Cancer Adult Refractory Cancer Endometrial Carcinoma (EC)Squamous Head and Neck Carcinoma pMMR/MSS Adenocarcinoma of the Colon or Rectum

Summary

This is a Phase 1 and Phase 2 study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study tests a new drug called GV20-0251 in patients with various solid tumors (cancers that form in organs or tissues). It's an early-phase trial to evaluate safety and find the right dose. Multiple cancer types may be eligible. **You may be eligible if...** - You are 18 or older - You have a solid tumor cancer confirmed by biopsy - You have already received prior standard treatments - You are in reasonably good overall health **You may NOT be eligible if...** - You have not tried prior standard treatments - You have serious organ problems or active infections - You are pregnant or breastfeeding - Your cancer is a blood cancer (not a solid tumor) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGGV20-0251

Part A: Increasing doses of GV20-0251 administered by intravenous (IV) infusion once every 3 weeks Part B: GV20-0251 preliminary RP2D administered by IV infusion once every 3 weeks

Locations(3)

Beijing Cancer Hospital

Beijing, Beijing Municipality, China

Cancer Hospital, Chinese Academy of Medical Sciences

Beijing, Beijing Municipality, China

Shanghai Pulmonary Hospital

Shanghai, Shanghai Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07070518

Related Trials

BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)

NCT071935119 locations

Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).

NCT066076921 location

Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors

NCT074245475 locations

A Clinical Study of Personalized Self-DC Vaccine Targeting Neoantigen in Treatment of Advanced Solid Tumor

NCT066821171 location

Effect of Meal Timing During Cancer Treatment in Patients in Alaska: A Randomized Clinical Trial

NCT068021721 location